Inhibikase Therapeutics, Inc.

DB:IQT0 Stock Report

Market Cap: €7.0m

Inhibikase Therapeutics Management

Management criteria checks 1/4

Inhibikase Therapeutics' CEO is Milton Werner, appointed in Jun 2010, has a tenure of 13.25 years. total yearly compensation is $744.06K, comprised of 67.3% salary and 32.7% bonuses, including company stock and options. directly owns 16.63% of the company’s shares, worth €1.16M. The average tenure of the management team and the board of directors is 8.9 years and 2.8 years respectively.

Key information

Milton Werner

Chief executive officer

US$744.1k

Total compensation

CEO salary percentage67.3%
CEO tenure13.3yrs
CEO ownership16.6%
Management average tenure8.9yrs
Board average tenure2.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Milton Werner's remuneration changed compared to Inhibikase Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2023n/an/a

-US$19m

Mar 31 2023n/an/a

-US$18m

Dec 31 2022US$744kUS$501k

-US$18m

Sep 30 2022n/an/a

-US$19m

Jun 30 2022n/an/a

-US$19m

Mar 31 2022n/an/a

-US$17m

Dec 31 2021US$611kUS$455k

-US$15m

Sep 30 2021n/an/a

-US$11m

Jun 30 2021n/an/a

-US$7m

Mar 31 2021n/an/a

-US$5m

Dec 31 2020US$961kUS$293k

-US$3m

Sep 30 2020n/an/a

-US$2m

Jun 30 2020n/an/a

-US$3m

Mar 31 2020n/an/a

-US$5m

Dec 31 2019US$385kUS$293k

-US$6m

Sep 30 2019n/an/a

-US$7m

Mar 31 2019n/an/a

-US$4m

Dec 31 2018US$535kUS$452k

-US$2m

Compensation vs Market: Milton's total compensation ($USD744.06K) is above average for companies of similar size in the German market ($USD418.12K).

Compensation vs Earnings: Milton's compensation has increased whilst the company is unprofitable.

CEO

Milton Werner (59 yo)

13.3yrs

Tenure

US$744,055

Compensation

Dr. Milton H. Werner, Ph D., serves as the Chief Executive Officer and President at Inhibikase Therapeutics, Inc. since June 2010. Prior to founding Inhibikase, From May 2007 until August 2008, Dr. Werner...

Leadership Team

NamePositionTenureCompensationOwnership
Milton Werner
CEO, President & Director13.3yrsUS$744.06k16.63%
€ 1.2m
Joseph Frattaroli
Chief Financial Officer5.4yrsUS$574.77k0.012%
€ 859.0
Roger Rush
Head of Preclinical Research8.7yrsno datano data
Surendra Singh
Head of Chemistry9.1yrsno datano data
Charles Olanow
CEO of Clintrex Research Corporation & Member of Scientific Advisory Boardno datano datano data
Dan Williams
Controllerno datano datano data

8.9yrs

Average Tenure

Experienced Management: IQT0's management team is seasoned and experienced (8.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Milton Werner
CEO, President & Director13.3yrsUS$744.06k16.63%
€ 1.2m
Charles Olanow
CEO of Clintrex Research Corporation & Member of Scientific Advisory Boardno datano datano data
Paul Grint
Independent Director2.8yrsUS$84.62k0%
€ 0
Dennis Berman
Independent Director2.8yrsUS$78.62k0%
€ 0
Kenneth Marek
Member of Scientific Advisory Boardno datano datano data
Jeffrey Kordower
Member of Scientific Advisory Boardno datano datano data
Roy Freeman
Independent Director2.8yrsUS$69.62k0%
€ 0
Robert Hauser
Member of Scientific Advisory Boardno datano datano data
Karl Kieburtz
Member of Scientific Advisory Boardno datano datano data
Gisele Dion
Independent Directorless than a yearUS$58.89kno data
Ted Dawson
Member of Scientific Advisory Boardno datano datano data
Valina Dawson
Member of Scientific Advisory Boardno datano datano data

2.8yrs

Average Tenure

65yo

Average Age

Experienced Board: IQT0's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/09/27 23:46
End of Day Share Price 2023/06/30 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Inhibikase Therapeutics, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WhiteH.C. Wainwright & Co.
Yuchen DingJefferies LLC
Jason McCarthyMaxim Group